UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000024574 |
|---|---|
| Receipt number | R000028278 |
| Scientific Title | Clinical trial of tocilizumab versus cyclophosphamide for microscopic polyangiitis and granulomatosis with polyangiitis |
| Date of disclosure of the study information | 2017/05/01 |
| Last modified on | 2019/05/07 11:38:41 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Clinical trial of tocilizumab versus cyclophosphamide for microscopic polyangiitis and granulomatosis with polyangiitis
Acronym
AAVTCZ
Scientific Title
Clinical trial of tocilizumab versus cyclophosphamide for microscopic polyangiitis and granulomatosis with polyangiitis
Scientific Title:Acronym
AAVTCZ
Region
| Japan |
Condition
Condition
Microscopic polyangiitis (MPA)
Granulomatosis with polyangiitis (GPA)
Classification by specialty
| Pneumology | Nephrology | Neurology |
| Clinical immunology | Ophthalmology | Dermatology |
| Oto-rhino-laryngology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To compare efficacy and safety between the treatment with intravenous tocilizumab (TCZ) plus high dose glucocorticoids (GC) and the treatment with intravenous cyclophosphamide (IVCY) plus high dose GC, in active patients with MPA and GPA.
Basic objectives2
Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Others
Developmental phase
Phase II
Assessment
Primary outcomes
The percentage of participants in complete remission at week 24 after randomization.
Complete remission is defined as BVAS v3 = 0 (at week 20 and 24) and daily prednisone at a dose of 7.5mg at week 24.
Key secondary outcomes
Percentage of participants maintaining complete remission (BVAS v3 = 0 and daily prednisolone at a dose of 7.5mg) during week 24 to 52 after randomization.
Percentage of participants who achieved BVAS v3 = 0 at two consecutive visits during 52 weeks after randomization.
Time from randomization to achieving BVAS v3 = 0 at two consecutive visits.
Percentage of participants who were able to taper daily prednisolone to a dose of 7.5mg during 52 weeks after randomization.
Time from randomization to tapering daily prednisolone to a dose of 7.5mg.
Total dosage of prednisolone.
Percentage of participants who had flare.
Time from randomization to first flare.
Changes of BVAS score by categories.
VDI
SF-36
EQ5D
Safety
Pharmacokinetics
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Cluster
Blinding
Open -but assessor(s) are blinded
Control
Active
Stratification
NO
Dynamic allocation
YES
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
TCZ group
Week 0-16: TCZ (8mg/kg) will be administrated intravenously every 2 weeks.
Week 20 and 24: TCZ (8mg/kg) will be administrated intravenously every 4 weeks.
If a participant does not achieve BVAS v3=0 at week 16, he/she can receive TCZ every 2 weeks until week 24.
Week 28-52: If a participant achieves complete remission at week 24, he/she will receive TCZ (8mg/kg) intravenously every 4 weeks until week 48.
PSL
PSL will be prescribed by the same schedule to both treatment groups.
Week 0-24: Oral PSL will be given at a dose of 0.8 mg/kg/day during first 4 weeks. And then, PSL will be tapered according to the prefixed schedule.
Week 25-52: Participants continue taking oral PSL at a dose of 7.5mg per day.
Interventions/Control_2
IVCY group
Week 0-24: CY (15mg/kg, doses will be modified for renal dysfunction) will be administrated intravenously every 4 weeks (at least 3 times, up to 6 times).
From 4 weeks after the last IVCY to week 52: If a participants achieves complete remission 4 weeks after the last IVCY, he/she will take azathioprine (AZA) orally every day and continue until week 52.
PSL
PSL will be prescribed by the same schedule to both treatment groups.
Week 0-24: Oral PSL will be given at a dose of 0.8 mg/kg/day during first 4 weeks. And then, PSL will be tapered according to the prefixed schedule.
Week 25-52: Participants continue taking oral PSL at a dose of 7.5mg per day.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 85 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1 Those with ANCA positive active MPA or GPA according to the diagnostic criteria of Japanese MHLW, or those with ANCA positive pauci-immune glomerulonephritis without non-renal vasculitis. They must have newly diagnosed MPA or GPA, or have a disease flare that fulfills the inclusion criteria.
2 They must be 20 years of age or older and be under 80 years old.
3 They must weigh at least 40 kg.
4 They must have active disease with BVAS v3 more than 3 with one or more of the major BVAS items. Or they must have active disease severe enough to require treatment with CY (i.e., an organ threatening disease if not treated appropriately) according to the discretion of site investigators.
5 Serum C-reactive protein level must be grater than1.0 mg/dl.
6 They must be willing to practice medically acceptable contraception until 70 days after the last administration of TCZ and until 90 days after the last administration of IVCY or AZA.
7 For female participants, they must be willing to refrain from breastfeeding throughout the trial.
8 They must be willing to comply with study procedures, including completion of all visits and treatments
9 They must be willing and able to provide informed consent.
Key exclusion criteria
Exclusion Criteria Patients who meet any of these criteria will not be enrolled in this study:
Eosinophilic granulomatosis with polyangiitis or anti-glomerular basement membrane antibody disease patients.
Other collagen diseases or systemic autoimmune diseases patients.
Severity: limited disease according to EUVAS criteria.
Those having serious lung, renal or heart disease.
Those having infarction or bleeding of gastrointestinal tract or having diverticulitis..
Those having a history of severe drug allergic reactions.
Those having an active infection or a deep-seated infection within 6 months of randomization.
Those having active hepatitis B or a history of infection with HBV.
Those having positive anti-HBs antibody or anti-HBc antibody, and HBV-DNA.
Those having active hepatitis C or a history of hepatitis C.
Those having an ALT or AST level greater than 2.5 times of the upper limit of normal.
Those having active tuberculosis or mycosis
Those having CMV antigenemia
They have or have a history of malignancy, leukemia, lymphoma or lymphoproliferative disease in the past 5 years.
Those having uncontrolled other disease.
Those having a white blood cell count less than 4,000/mm3 or a platelet count less than 120,000/mm3.
Those who have received TCZ or other biological agents.
Those who were intolerant to CYC or AZA.
Those who started GC or increased a dosage of GC within 4 weeks prior to enrollment.
Those who started GC at or increased a dosage of GC to a prednisone-equivalent dose greater than 25mg per day between 5 and 8weeks prior to enrollment.
Those who started or increased a dosage of immunosuppressive agents except for GC within 8 weeks prior to enrollment.
Those who were treated with plasma exchange or IVIG within 4 weeks prior to enrollment.
Those who received a live vaccine within 4 weeks prior to enrollment.
Those who were enrolled in another clinical trial and received an investigational agent within 12 weeks prior to enrollment.
Target sample size
48
Research contact person
Name of lead principal investigator
| 1st name | Masayoshi |
| Middle name | |
| Last name | Harigai |
Organization
Tokyo women's medical university
Division name
Institute of Rheumatology
Zip code
1628666
Address
8-1 kawada-cho shinjyuku-ku Tokyo Japan
TEL
03-3353-8111
harigai.masayoshi@twmu.ac.jp
Public contact
Name of contact person
| 1st name | Michi |
| Middle name | |
| Last name | Tsutsumino |
Organization
Tokyo women's medical university
Division name
Institute of Rheumatology
Zip code
1628666
Address
8-1 kawada-cho shinjyuku-ku Tokyo Japan
TEL
03-3353-8111
Homepage URL
tsutsumino.michi@twmu.ac.jp
Sponsor or person
Institute
Tokyo women's medical university
Institute of rheumatology
Institute
Department
Personal name
Funding Source
Organization
Japan Medical Association
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Hokkaido university hospital
Saitama medical center
Tokyo women's medical university hospital
Keio university hospital
Juntendo university hospital
Kyorin university hospital
St. Marianna university hospital
Okayama university hospital
Kagawa university hospital
Hospital of the university of occupational and environmental health, Japan
Tokyo Medical Center
Touhoku University Hospital
Kyusyu University Hospital
Hiroshima University Hospital
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Tokyo women's medical university Hospital
Address
8-1 kawada-cho shinjyuku-ku Tokyo Japan
Tel
03-5269-7839
ar.twmu-chiken-ar@smo-msr.co.jp
Secondary IDs
Secondary IDs
YES
Study ID_1
JMA-IIA00325
Org. issuing International ID_1
Japan Medical Association
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
東京女子医科大学病院（東京都）
北海道大学病院（北海道）
埼玉医科大学総合医療センター（埼玉県）
慶應義塾大学病院（東京都）
順天堂大学医学部附属順天堂医院（東京都）
杏林大学医学部付属病院（東京都）
聖マリアンナ医科大学病院（神奈川県）
岡山大学病院（岡山県）
香川大学医学部附属病院（香川県）
産業医科大学病院（福岡県）
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 05 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2016 | Year | 10 | Month | 30 | Day |
Date of IRB
Anticipated trial start date
| 2018 | Year | 07 | Month | 02 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2016 | Year | 10 | Month | 26 | Day |
Last modified on
| 2019 | Year | 05 | Month | 07 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028278
